Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Omega-3 wins 3 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Probably helps
18 of 27 studies with measurable effects showed benefit.
Top outcomes
OTC wellness: 10-50mg/day (some anxiety studies used higher acute doses ~300mg); take with a fat-containing meal (increases absorption several-fold). Prescription Epidiolex for epilepsy is dosed by body weight under medical supervision.
with-meals, evening
CBD oil/tincture (third-party tested for potency and purity)
2-3g combined EPA+DHA daily
With meals containing fat
Triglyceride form fish oil
Acute-4 weeks
1-8 weeks
Weeks
Acute
4-8 weeks
2-4 weeks
Immediate
4-12 weeks
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.
The New England journal of medicine (2017) · Rct · n=120
Convulsive seizures fell from 12.4 to 5.9/month with CBD vs 14.9 to 14.1 with placebo
Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial.
Lancet (London, England) (2018) · Rct
Significant reduction in drop-seizure frequency vs placebo
Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.
The New England journal of medicine (2018) · Rct
Fewer drop seizures vs placebo
Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer
The New England journal of medicine (2019) · Rct · n=25871
During a median follow-up of 5.3 years, a major cardiovascular event occurred in 386 participants in the n-3 group and in 419 in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.80 to 1.06; P=0.24).
Omega-3 fatty acids for intermittent claudication
The Cochrane database of systematic reviews (2024) · Meta analysis · n=1830
Omega-3 compared with a control may have little to no effect on ankle-brachial index (MD -0.02, 95% CI -0.08 to 0.04; 3 studies, 168 participants; very low-certainty evidence).
A systematic review and meta-analysis of the omega-3 fatty acids effects on brain-derived neurotrophic factor (BDNF)
Nutritional neuroscience (2024) · Meta analysis · n=587
The present systematic review and meta-analysis indicate the efficacy of omega-3 FAs in increasing the serum concentration of BDNF.
Based on multiple meta-analyses showing EPA-dominant formulas >1g/day most effective. Effects plateau around 2-2.5g. Adjunctive use with antidepressants shows better outcomes than monotherapy.
AI-estimated from published studies. Interpret as directional guidance.
Omega-3 has a higher evidence score (9/10 vs 5.8/10) and wins in 3 of 3 categories.
For reduce inflammation, Omega-3 has a higher relevance score (90 vs 42).
No known interactions between CBD and Omega-3 have been documented in our database. However, always consult a healthcare provider before combining supplements.